{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:28:45Z","timestamp":1792801725446,"version":"4.5.0"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    Minimal residual disease (MRD) has emerged as a key prognostic factor in multiple myeloma (MM), allowing a more accurate evaluation of treatment efficacy beyond conventional complete remission. High-sensitivity techniques, including next-generation flow cytometry (NGF), next-generation sequencing (NGS), and allele-specific oligonucleotide quantitative PCR, enable detection of residual disease at levels of 10\n                    <jats:sup>\u22125<\/jats:sup>\n                    \u201310\n                    <jats:sup>\u22126<\/jats:sup>\n                    . Achieving MRD negativity is consistently associated with prolonged progression-free survival (PFS) and overall survival (OS) across different disease settings. In 2024, the U.S. Food and Drug Administration Oncologic Drugs Advisory Committee unanimously recognized MRD negativity as a primary endpoint in MM clinical trials, reinforcing its role as a validated surrogate of clinical benefit. This review summarizes current MRD detection methods and discusses how MRD assessment, interpreted in the context of recent pivotal clinical trials, may provide a practical framework to guide future treatment strategies in MM.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2025.1740112","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T05:25:10Z","timestamp":1772169910000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["MRD in multiple myeloma: the clinical perspective"],"prefix":"10.3389","volume":"15","author":[{"given":"Tommaso","family":"Caravita di Toritto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Rago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000001197","article-title":"Advancing MRD Detection in Multiple Myeloma: Technologies, Applications, and Future Perspectives","volume":"48","author":"Chen","year":"2025","journal-title":"Am J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-025-01017-x","article-title":"Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma","volume":"22","author":"Paiva","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020284","article-title":"Potential future direction of measurable residual disease evaluation in multiple myeloma","volume":"142","author":"Mohty","year":"2023","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02020","article-title":"Minimal Residual Disease-Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials","volume":"43","author":"Shi","year":"2025","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-24-0292","article-title":"Minimal Residual Disease as an Early Endpoint for Accelerated Drug Approval in Myeloma: A Roadmap","volume":"6","author":"Landgren","year":"2025","journal-title":"Blood Cancer Discov"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03485-7","article-title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial","volume":"31","author":"Usmani","year":"2025","journal-title":"Nat Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00236-3","article-title":"Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial","volume":"10","author":"Costa","year":"2023","journal-title":"Lancet Haematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-177546.37410508","article-title":"Results of the Phase III Randomized Iskia Trial: Isatuximab\u2010Carfilzomib\u2010Lenalidomide\u2010Dexamethasone vs Carfilzomib\u2010Lenalidomide\u2010Dexamethasone as Pre\u2010Transplant Induction and Post\u2010Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients","volume":"142","author":"Gay","year":"2023","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01936","article-title":"Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible\/with no immediate intent for autologous stem cell transplantation","volume":"37","author":"Ocio","year":"2023","journal-title":"Leukemia"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1080\/10408363.2025.2512466","article-title":"Advances in multiple myeloma blood-based monitoring and its clinical applications","volume":"62","author":"Tzasta","year":"2025","journal-title":"Crit Rev Clin Lab Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264972","article-title":"New Developments in Myeloma Treatment and Response Assessment","volume":"64","author":"Kraeber-Bodere","year":"2023","journal-title":"J Nucl Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.217","article-title":"Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry","volume":"28","author":"Puig","year":"2014","journal-title":"Leukemia"},{"key":"B18","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3390\/jcm13010264","article-title":"Imaging of Multiple Myeloma: Present and Future","volume":"13","author":"Rodr\u00edguez-Laval","year":"2024","journal-title":"J Clin Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fnume.2021.808627","article-title":"18 F-FDG PET\/CT and MRI in the Management of Multiple Myeloma: A Comparative Review","volume":"1","author":"Mesguich","year":"2022","journal-title":"Front Nucl Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008733","article-title":"How I treat high-risk multiple myeloma","volume":"139","author":"Zamagni","year":"2022","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27526","article-title":"Clinical significance of complete remission and measurable residual disease in relapsed\/refractory multiple myeloma patients treated with T-cell redirecting immunotherapy","volume":"100","author":"Zabaleta","year":"2024","journal-title":"Am J Hematol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"104913","DOI":"10.1016\/j.critrevonc.2025","article-title":"Next-generation immunotherapy in relapsed\/refractory multiple myeloma: Strategies to achieve sustained MRD negativity","volume":"214","author":"Zhu","year":"2025","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1740112\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T05:25:11Z","timestamp":1772169911000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1740112\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":23,"alternative-id":["10.3389\/fonc.2025.1740112"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1740112","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"article-number":"1740112"}}